Dexamethasone acetate

DRUG19 trials

Conditions

Bone MetastasesDexamethasoneFractured Neck of FemurGlioblastoma MultiformeImpacted Third Molar ToothInflammationInterscalene BlockLeukemia

Early Phase 1

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

TerminatedNCT01878708

Dana-Farber Cancer InstituteRefractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma, T-Cell Lymphoma

Start: 2013-07-31End: 2017-02-28Updated: 2017-03-06

Evaluation of Preoperative Submucosal Dexamethasone in Third Molar Surgery

CompletedNCT02837614

Sun Yat-sen UniversityImpacted Third Molar Tooth

Start: 2015-10-31End: 2016-03-31Updated: 2016-07-19

Phase 1

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

CompletedNCT01421173

M.D. Anderson Cancer CenterLymphoma

Start: 2011-08-31End: 2015-09-30Updated: 2015-11-18

Phase 2

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

CompletedNCT00635154

Mayo ClinicMultiple Myeloma and Plasma Cell Neoplasm

Start: 2002-12-31End: 2010-11-30Updated: 2018-06-07

Early Treatment With Dexamethasone in Mild Acute Pancreatitis

WithdrawnNCT01247961

Brigham and Women's HospitalPatients With Acute Pancreatitis

Start: 2010-11-30End: 2011-06-30Updated: 2016-12-12

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

TerminatedNCT02419469

M.D. Anderson Cancer CenterLeukemia, Lymphoblastic Lymphoma, Lymphoma +1

Start: 2015-11-13End: 2017-06-22Updated: 2018-06-11

Phase 3

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00651261

Alliance for Clinical Trials in OncologyLeukemia

Start: 2008-04-30Updated: 2021-08-18

Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009

CompletedNCT01669499

UMC UtrechtBone Metastases

Start: 2012-01-31End: 2016-04-30Target: 411Updated: 2016-11-16

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

CompletedNCT01868269

Institut CurieNeuroblastoma, Opsoclonus Myoclonus Syndrome

Start: 2013-04-18End: 2025-01-17Updated: 2025-02-03

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

CompletedNCT01916252

PETHEMA FoundationMultiple Myeloma

Start: 2013-09-30End: 2016-11-16Target: 460Updated: 2017-09-27

MK-5684-003: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)

RecruitingCTIS2023-504899-25-00

Merck Sharp & Dohme LLCMetastatic castration resistant prostate cancer

Start: 2024-04-04Target: 393Updated: 2025-12-04

MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)

SuspendedCTIS2023-504957-11-00

Merck Sharp & Dohme LLCMetastatic castration resistant prostate cancer

Start: 2024-04-05Target: 401Updated: 2025-11-13

Phase 4

Single Dose of Dexamethasone in Femur Fractures

NCT01550146

Cork University HospitalFractured Neck of Femur

Start: 2009-07-31End: 2012-07-31Target: 40Updated: 2012-03-09

Prolongation of Pain Free Time by the Use of Dexamethasone in Peripheral Nerve Blockade

NCT02178449

Landesklinikum Sankt PoltenDexamethasone, Interscalene Block, Low Volume Regional Anesthesia +1

Start: 2014-03-31End: 2015-05-31Target: 109Updated: 2014-06-30

The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis

NCT02588196

Hui BuTuberculous Meningitis

Start: 2015-11-30Target: 200Updated: 2015-10-29

Unknown Phase

Effects of Steroid Tapering on Functional Capacity and Neurocognition

WithdrawnNCT01169415

Duke UniversityGlioblastoma Multiforme

Start: 2010-06-30End: 2014-05-31Updated: 2014-05-19

Comparison of Efficacy of Nebulizing Budesonide and Intravenous Dexamethasone Before Extubation on Prevention of Post-extubation Complications in Intensive Care Unit Patients

NCT01854515

Saeed AbbasiRespiratory Sounds

Start: 2012-03-31Target: 90Updated: 2013-05-15

Interest of Cryotherapy or Cortisone Aerosol Therapy in Early Post-operative Swallowing Disorders Following Total Thyroidectomy

CompletedNCT02855866

Centre Hospitalier Universitaire DijonPost-operative Swallowing Disorders, Thyroidectomy

Start: 2013-09-03End: 2015-02-20Updated: 2018-12-21

Anti-inflammatory Steroids in the Prevention of Tooth Sensitivity

CompletedNCT02956070

Universidade Federal FluminenseInflammation

Start: 2015-10-31End: 2016-05-31Updated: 2020-11-25

Blood2025-11-03

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood2025-11-03

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.

2025-10-012 citations

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Blood2024-09-1816 citations

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

2024-06-013 citations

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood2023-12-0427 citations

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

Frontiers in Oncology2023-11-0216 citations

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

Haematologica2023-08-304 citations

P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON

HemaSphere2022-06-01

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

Blood Advances2022-02-1446 citations

Midostaurin in Patients (Pts) with Newly Diagnosed <i>FLT3</i>-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Blood2021-11-056 citations

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

Blood Advances2021-09-2944 citations

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, <i>FLT3</i>-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Blood2020-11-058 citations

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

Blood Advances2020-10-1356 citations

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Blood2020-07-21126 citations

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Blood2020-04-1634 citations

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.

2019-10-01157 citations

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Blood Advances2019-06-0616 citations

PS1352 DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS

HemaSphere2019-06-01

PS968 GENETIC LANDSCAPE OF FLT3‐MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE)